Bio-Connect

DR5 antibody [DR5-01-1] (PE)

Research Use Only
GTX80180
GeneTex
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman
TargetTNFRSF10B
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    DR5 antibody [DR5-01-1] (PE)
  • Delivery Days Customer
    9
  • Antibody Specificity
    This antibody recognizes an extracellular domain of TRAIL-R2 (DR5).
  • Applications
    Flow Cytometry
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    DR5-01-1
  • Concentration
    0.1 mg/ml
  • Conjugate
    RPE
  • Gene ID8795
  • Target name
    TNFRSF10B
  • Target description
    TNF receptor superfamily member 10b
  • Target synonyms
    apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; DR5; Fas-like protein; KILLER; KILLER/DR5; p53-regulated DNA damage-inducible cell death receptor(killer); TNF-related apoptosis-inducing ligand receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9
  • Host
    Mouse
  • Isotype
    IgG1
  • Scientific Description
    The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene. [provided by RefSeq, Mar 2009]
  • Reactivity
    Human
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors. ?rtykov ?? et al., 2020 Apr 30, Cancers (Basel)
    Read more
  • Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile. Yagolovich AV et al., 2020 Apr, Transl Oncol
    Read more